While biopharma was dominated by COVID-19, which prompted a surge of research and business activity, the industry also saw developments that will position it for further growth even after the virus is brought under control. Besides building momentum against COVID-19 in 2021, biopharma will accelerate its progress in genome editing, gene and cell therapy, synthetic biology, and other crucial areas